Vesigen Therapeutics
Vesigen Therapeutics was a Cambridge, MA-based pre-clinical biotech (founded 2019) that developed the ARMMs extracellular vesicle platform, licensed from Harvard, for non-viral delivery of gene-editing therapeutics targeting neurodegenerative diseases such as Friedreich's Ataxia, before being acquired by Turn Biotechnologies in March 2025.
- Company typePrivate
- Founded2019
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vesigen Therapeutics does
Vesigen Therapeutics was a Cambridge, Massachusetts-based, privately held biotechnology company founded in 2019 that developed a non-viral drug delivery platform based on ARMMs (ARRDC1 Mediated Microvesicles), an engineered human extracellular vesicle technology licensed from Harvard University. The platform was designed to transport signaling molecules between cells and deliver therapeutic cargoes—including proteins, RNA-based therapies, and CRISPR-Cas genome editing complexes—to targeted cell types with high encapsulation efficiency and reduced off-target effects. The company's primary research focus was the application of this delivery system to neurodegenerative conditions, with particular emphasis on Friedreich's Ataxia, supported in part by a 2023 General Research Grant from the Friedreich's Ataxia Research Alliance (FARA).
Vesigen's competitive positioning rested on a technology architecture that was described as biocompatible, redosable, simpler to manufacture than viral vectors, tissue-targetable through appended cell-targeting molecules, and capable of carrying large, diverse cargoes. The company was backed by a syndicate that included Leaps by Bayer (Bayer Healthcare LLC), Morningside Group, Alexandria Venture Investments, and Linden Lake Ventures, following a $28.5 million Series A financing in July 2020. Leadership consisted of CEO Paulash Mohsen, co-founder Quan Lu, and director Lucio Iannone, with an organizational footprint of 11–50 employees.
On March 26, 2025, Turn Biotechnologies acquired the ARMMs vesicular technology and all associated assets from Vesigen, including the Harvard University license and related intellectual property. Following this transaction, Vesigen's operating status is recorded as acquired, and its technology now sits within Turn Bio's pre-clinical epigenetic reprogramming pipeline. As a result, Vesigen no longer operates as an independent commercial entity, and no standalone revenue, product pricing, or go-to-market mechanics were disclosed in the source data.
Vesigen Therapeutics firmographics
Firmographics- Name
- Vesigen Therapeutics
- Legal name
- Vesigen Therapeutics
- Website
- https://vesigentx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Vesigen Therapeutics was a Cambridge, MA-based pre-clinical biotech (founded 2019) that developed the ARMMs extracellular vesicle platform, licensed from Harvard, for non-viral delivery of gene-editing therapeutics targeting neurodegenerative diseases such as Friedreich's Ataxia, before being acquired by Turn Biotechnologies in March 2025.
- Ownership category
- akta.pro rank
Vesigen Therapeutics industry classification
Industry- Product category
- Biotechnology Drug Delivery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL), Neurology/CNS Gene Therapies (HLAAACAH)
Keywords
Where Vesigen Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Vesigen Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Vesigen Therapeutics product offering
Product offeringCore offering
Vesigen Therapeutics developed the ARMMs (ARRDC1 Mediated Microvesicles) platform, a non-viral delivery technology based on engineered human extracellular vesicles licensed from Harvard University. The platform was designed to deliver therapeutic cargoes including CRISPR-Cas genome editing complexes, proteins, and RNA-based therapies to targeted cells, with primary applications in treating Friedreich's Ataxia and other neurodegenerative conditions.
Product overview
Vesigen Therapeutics is a biotechnology company that developed the ARMMs (ARRDC1 Mediated Microvesicles) technology - a non-viral drug delivery platform using engineered human extracellular vesicles. The company was focused on applying this delivery technology for CRISPR-Cas genome editing complexes to treat neurodegenerative conditions. The technology was licensed from Harvard University and has since been acquired by Turn Biotechnologies. The company's primary research direction was targeted genome editing therapeutics for Friedreich's Ataxia.
Differentiator
Problem solved
Functional benefit
Products and services
- ARMMs (ARRDC1 Mediated Microvesicles) Platform
Companies that use Vesigen Therapeutics
Customer profileIdeal customer profiles1 record
Vesigen Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Vesigen Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Harvard UniversitycoreVesigen Therapeutics developed the ARMMs technology under a license from Harvard University. The technology is based on ARRDC1-Mediated Microvesicles derived from human extracellular vesicles.
- Turn BiotechnologiescoreTurn Biotechnologies acquired the ARMMs vesicular technology and all associated assets from Vesigen Therapeutics. This transfer included the license to the technology from Harvard University and all related intellectual property.
- FARA (Friedreich's Ataxia Research Alliance)coreVesigen received a FARA General Research Grant to develop a targeted genome editing therapeutic strategy for Friedreich's Ataxia. The company will evaluate its ARMM technology as a delivery vehicle for CRISPR-Cas genome editing complexes to treat neurodegenerative conditions associated with FA.
Recent moves4 records
Expansion highlights3 records
Vesigen Therapeutics competitors and assessment
Company assessmentDirect peers
- Codiak BioSciences: Developed exosome-based therapeutic platforms (engEx) for delivering diverse cargoes including RNA, proteins, and gene editors. Direct competitor to Vesigen's ARMMs extracellular vesicle approach with similar cargo flexibility and target-tissue ambitions.
- Evox Therapeutics: Engineering extracellular vesicles (exosomes) for delivery of nucleic acids, proteins, and gene editors to specific tissues. Closest direct peer in modality, platform architecture, and target indications including CNS diseases.
- Arcturus Therapeutics: Clinical-stage RNA medicines company using LNP and other delivery systems to enable mRNA, siRNA, and CRISPR-based therapeutics. Comparable in the RNA delivery space and in targeting rare genetic diseases including Friedreich's Ataxia.
- Generation Bio: Develops non-viral lipid nanoparticle-based gene therapy delivery platforms for both rare and large patient populations. Direct peer in pursuing non-viral alternatives to AAV for gene therapy cargoes.
- Acuitas Therapeutics: Specializes in lipid nanoparticle delivery technology for nucleic acid therapeutics, with partnerships across the gene therapy and mRNA industries. Key competitor in non-viral delivery of RNA and gene editing cargoes.
Broad incumbents
- Intellia Therapeutics: Clinical-stage in vivo CRISPR/Cas9 gene editing company with proprietary LNP delivery for liver-targeted therapies. Broader incumbent in the gene editing space that Vesigen's ARMMs platform could complement or compete with.
- Editas Medicine: Clinical-stage genome editing company using both AAV and non-viral delivery approaches for in vivo and ex vivo therapies. Larger incumbent pursuing the same therapeutic cargo space as Vesigen's platform.
Emerging players
- Laronde (now part of Sail Biomedicines): Developed endless RNA (eRNA), a closed-loop RNA therapeutic platform with proprietary delivery. Emerging peer pursuing non-viral delivery of RNA-based cargoes, with overlapping strategic intent to Vesigen's RNA delivery applications.
- Verve Therapeutics: Clinical-stage company developing in vivo base editing therapies for cardiovascular disease, using LNP-based delivery of gene editing cargoes to the liver. Comparable in cargo class (gene editors) and non-viral delivery approach.
- Capricor Therapeutics: Develops cell-derived exosome-based therapeutics (CAP-2003) for inflammatory and rare diseases. Comparable in using extracellular vesicles as a therapeutic delivery modality, with overlap in rare disease focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Vesigen Therapeutics social profiles
Digital presenceVesigen Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vesigen Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Vesigen Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vesigen Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vesigen Therapeutics
What does Vesigen Therapeutics do?
Vesigen Therapeutics developed the ARMMs (ARRDC1 Mediated Microvesicles) platform, a non-viral delivery technology based on engineered human extracellular vesicles licensed from Harvard University. The platform was designed to deliver therapeutic cargoes including CRISPR-Cas genome editing complexes, proteins, and RNA-based therapies to targeted cells, with primary applications in treating Friedreich's Ataxia and other neurodegenerative conditions.
Is Vesigen Therapeutics a public or private company?
Vesigen Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Vesigen Therapeutics founded?
Vesigen Therapeutics was founded in 2019. It employs 11 to 50 people.
Where is Vesigen Therapeutics based?
Vesigen Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are Vesigen Therapeutics's main competitors?
Direct peers on record are Codiak BioSciences, Evox Therapeutics, Arcturus Therapeutics, Generation Bio and Acuitas Therapeutics. Broad incumbents are Intellia Therapeutics and Editas Medicine. Emerging players are Laronde (now part of Sail Biomedicines), Verve Therapeutics and Capricor Therapeutics.
Does Vesigen Therapeutics have an API?
No public API is recorded for Vesigen Therapeutics.
What industry is Vesigen Therapeutics in?
Vesigen Therapeutics's product category is Biotechnology Drug Delivery Platform. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.